1. Pink Sheet

Bigger And Smaller? Pfizer Pursues AstraZeneca But Hasn’t Given Up On A Split

 
• By Jessica Merrill

A Pfizer break up is still an option even if the company completes a mega-merger with AstraZeneca, CEO Ian Read said May 5. The company’s first quarter sales and earnings results highlighted how important completing a transaction could be for the company, with sales down 9% and earnings down 15%.

A breakup of Pfizer Inc. remains on the table, even if the company completes a mega-merger with AstraZeneca PLC, CEO Ian Read confirmed during the company’s first quarter sales and earnings call May 5.

He said Pfizer would work to preserve “optionality” when it comes to a business separation regardless of

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D